Fecal microbiota transplant promotes response in immunotherapy-refractory melanoma patients
- PMID:33303685
- DOI: 10.1126/science.abb5920
Fecal microbiota transplant promotes response in immunotherapy-refractory melanoma patients
Abstract
The gut microbiome has been shown to influence the response of tumors to anti-PD-1 (programmed cell death-1) immunotherapy in preclinical mouse models and observational patient cohorts. However, modulation of gut microbiota in cancer patients has not been investigated in clinical trials. In this study, we performed a phase 1 clinical trial to assess the safety and feasibility of fecal microbiota transplantation (FMT) and reinduction of anti-PD-1 immunotherapy in 10 patients with anti-PD-1-refractory metastatic melanoma. We observed clinical responses in three patients, including two partial responses and one complete response. Notably, treatment with FMT was associated with favorable changes in immune cell infiltrates and gene expression profiles in both the gut lamina propria and the tumor microenvironment. These early findings have implications for modulating the gut microbiota in cancer treatment.
Copyright © 2021 The Authors, some rights reserved; exclusive licensee American Association for the Advancement of Science. No claim to original U.S. Government Works.
Comment in
- Microbiome transplant-induced response to immunotherapy.Stower H.Stower H.Nat Med. 2021 Jan;27(1):21. doi: 10.1038/s41591-020-01220-6.Nat Med. 2021.PMID:33442010No abstract available.
- Modulating gut microbiota to treat cancer.Woelk CH, Snyder A.Woelk CH, et al.Science. 2021 Feb 5;371(6529):573-574. doi: 10.1126/science.abg2904.Science. 2021.PMID:33542126No abstract available.
- Targeting the Microbiome to Overcome Resistance.Simpson RC, Shanahan E, Scolyer RA, Long GV.Simpson RC, et al.Cancer Cell. 2021 Feb 8;39(2):151-153. doi: 10.1016/j.ccell.2021.01.016.Cancer Cell. 2021.PMID:33561397
- Overcoming hurdles in cancer immunotherapy.York A.York A.Nat Rev Microbiol. 2021 Apr;19(4):222-223. doi: 10.1038/s41579-021-00526-7.Nat Rev Microbiol. 2021.PMID:33597747No abstract available.
- First clinical proof-of-concept that FMT can overcome resistance to ICIs.Elkrief A, Routy B.Elkrief A, et al.Nat Rev Clin Oncol. 2021 Jun;18(6):325-326. doi: 10.1038/s41571-021-00502-3.Nat Rev Clin Oncol. 2021.PMID:33742164No abstract available.
- Fecal microbiota transplantation: can it circumvent resistance to PD-1 blockade in melanoma?Derosa L, Zitvogel L.Derosa L, et al.Signal Transduct Target Ther. 2021 May 8;6(1):178. doi: 10.1038/s41392-021-00585-5.Signal Transduct Target Ther. 2021.PMID:33966043Free PMC article.No abstract available.
- Fecal microbiota transplants may aid melanoma immunotherapy resistance.Fillon M.Fillon M.CA Cancer J Clin. 2021 Jul;71(4):285-286. doi: 10.3322/caac.21676. Epub 2021 Jun 8.CA Cancer J Clin. 2021.PMID:34101828No abstract available.
- Harnessing the microbiome to restore immunotherapy response.Bullman S, Eggermont A, Johnston CD, Zitvogel L.Bullman S, et al.Nat Cancer. 2021 Dec;2(12):1301-1304. doi: 10.1038/s43018-021-00300-x.Nat Cancer. 2021.PMID:35121929No abstract available.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Molecular Biology Databases